Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: preservation (8), upholding (44), protection (654), continuation (43), continuance (2), safeguarding (101), repairs (104)

Azacitidine Oral

Description: Chemotherapy Protocol ACUTE MYELOID LEUKAEMIA -AZACITADINE (ORAL) Regimen • AML – AZACITADINE (ORAL) Indication Oral azacitidine as maintenance therapy in newly diagno
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/Azacitidine-Oral.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamide-Obinutuzum
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf

O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine (O-CHOP) Regimen • NHL – O-CHOP-Cyclophospham
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CHOP-Cyclophosphamide-Doxorubicin-Obinutuzumab-Prednisolone-Vincristine.pdf

ACCORD-2 example sub-protocol

Description: CONFIDENTIAL ACCORD-2-002 - Sub protocol for Bemcentinib (Amendment 01) TITLE PAGE Master Protocol Title: ACCORD-2: A Multicentre,
Url: /Media/Southampton-Clinical-Research/COVID-19/ACCORD/ACCORD-2-example-sub-protocol.pdf

Annual report 2021-2022

Description: 2021/22 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2021/22 Prese
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/Annual-report-2021-2022.pdf

Papers Trust Board 6 June 2024

Description: Date Time Location Chair Apologies Agenda Trust Board – Open Session 06/06/2024 9:00 - 13:00 Conference Room, Heartbeat/Microsoft Teams Jenni Do
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Papers-Trust-Board-6-June-2024.pdf

Trastuzumab (21 day-Load)

Description: Chemotherapy Protocol BREAST CANCER TRASTUZUMAB (21 day-Load) Regimen • Breast Cancer – Trastuzumab (21 day-Load) Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Trastuzumab-21-day-Load.pdf

Annual-report-and-quality-account-2019-20

Description: ANNUAL REPORT AND ACCOUNTS 2019/20 Incorporating the quality account 2019/20 Page 2 University Hospital Southampton NHS Foundation Trust Annual
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-and-quality-account-2019-202.pdf

Annual report 20-21

Description: 2020/21 Incorporating the quality report University Hospital Southampton NHS Foundation Trust Annual Report and Accounts 2020
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Annual-reports-and-quality-accounts/annual-report-20-21.pdf

Bendamustine-Obinutuzumab

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Bendamustine-Obinutuzumab Regimen • NHL – Bendamustine-Obinutuzumab Indication • Obinutuzumab in combination wit
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Bendamustine-Obinutuzumab.pdf

31 to 40 of 153

Previous … 2 3 4 5 6 … Next